He anticipates that doctors and patients may especially turn to pills for weight maintenance, after reaching a weight-loss plateau on injectable drugs
In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking GLP-1 medications were less than half as likely to die within five years compared to those who werent on the drugs (15.5% versus 37.1%)
The triple agonist mechanism means appetite suppression builds differently than with dual agonists alone
Top-line outcomes at the 48-week primary endpoint, by dose: Notable Phase 2 finding particularly relevant to the 10mg vial: the 1mg/week cohort still produced 8.7% mean weight loss over 48 weeks, clinically meaningful activity even at sub-therapeutic doses relative to the 12mg maximum
M., Fernndez-Fernndez, B., Ortiz, A., & Grriz-Zambrano, C
DPP4 Inhibitors effect on GLP-1 secretion GLP-1RAs provide superior glycemic control and weight loss vs